Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2020, with a specific transaction date of February 10, 2020. The report serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) under the UK Market Abuse Regulation.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It reports specific transaction data for a PDMR:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Type: Exercise of options followed by immediate sale.
- Volume: 7,670 ADSs.
- Exercise Price: $37.32 per ADS.
- Sale Price: $44.2548 per ADS.
- Exchange: New York Stock Exchange (XNYS).
Material Changes
The filing does not contain comparative financial data or material changes to the company's operational performance versus prior periods. The only reported change is the reduction of the PDMR's option holdings and the corresponding increase in cash proceeds from the sale.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of a specific insider transaction.
Investor Verification Points
- Verify the identity of the PDMR: Mr. N Hirons, SVP, Global Ethics & Compliance.
- Confirm the source of the shares: Options granted on February 22, 2010, under the GlaxoSmithKline Share Option Plan.
- Note the timing: The exercise and sale occurred on the same day (February 10, 2020).
- Calculate the gross proceeds: 7,670 shares sold at $44.2548 equals approximately $339,434.